BI-754111
- Generic Name
- BI-754111
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT03964233
- Locations
- 🇫🇷
INS Bergonie, Bordeaux, France
🇫🇷CTR Leon Berard, Lyon, France
🇫🇷INS Gustave Roussy, Villejuif, France
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
- Conditions
- Carcinoma, Non-Small-Cell LungHead and Neck Neoplasms
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT03780725
- Locations
- 🇳🇱
Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands
Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
- Conditions
- Neoplasm Metastasis
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 212
- Registration Number
- NCT03697304
- Locations
- 🇺🇸
Florida Cancer Specialists-Fort Myers-52980, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists-Saint Petersburg-52979, Saint Petersburg, Florida, United States
🇺🇸Florida Cancer Specialists-Sarasota-61670, Tallahassee, Florida, United States
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 146
- Registration Number
- NCT03433898
- Locations
- 🇯🇵
Kanagawa Cancer Center, Kanagawa, Yokohama, Japan
🇯🇵Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Kashiwa, Japan
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasms
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 172
- Registration Number
- NCT03156114
- Locations
- 🇪🇸
Hospital Universitari Dexeus, Barcelona, Spain
🇪🇸Hospital Politècnic La Fe, Valencia, Spain
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.